Clinical Trials for Refractory Mantle Cell Lymphoma

Find clinical trials for refractory mantle cell lymphoma. Discover research opportunities and treatment options in your area.

11 Active Trials Found

Showing 11 trials on this page

Page 1 of 1

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT ID: NCT07003295

This clinical trial is studying two drugs, glofitamab and obinutuzumab, to see how safe and effective they are for patients with mantle cell lymphoma, a type of blood cancer, that has returned afte...

Not yet recruiting

Phase: PHASE2 Type: interventional

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT ID: NCT06839053

This clinical trial is looking at a new treatment approach for patients with certain types of blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mant...

Recruiting

Phase: PHASE2 Type: interventional Locations: Seattle, Washington, United States

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT ID: NCT03147885

This clinical trial is studying a new treatment approach for patients with advanced B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and others. The trial combines a ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Detroit, Michigan, United States, La Jolla, California, United States

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT ID: NCT05453396

This clinical trial is studying a new treatment called loncastuximab tesirine for patients with specific types of B-cell cancers that have either come back after previous treatments or did not resp...

Recruiting

Phase: PHASE2 Type: interventional Locations: Seattle, Washington, United States

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT ID: NCT06859008

This clinical trial is studying the combination of two medications, zanubrutinib and sonrotoclax, to treat patients from underrepresented racial and ethnic backgrounds who have a type of blood canc...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT ID: NCT04054167

This clinical trial is studying whether giving very low doses of radiation before or after a targeted therapy can help patients with mantle cell lymphoma, especially those whose cancer has come bac...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

NCT ID: NCT05249959

This clinical trial is studying a new treatment called loncastuximab tesirine for patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received certain therapies. The...

Recruiting

Phase: PHASE2 Type: interventional Locations: Brescia, , Italy, Cuneo, , Italy +19 more

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT ID: NCT04484012

This clinical trial is looking at a new treatment option for patients with mantle cell lymphoma, a type of cancer that has either come back or hasn't responded to previous treatments. The study com...

Recruiting

Phase: PHASE2 Type: interventional Locations: Duarte, California, United States

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT ID: NCT05910801

This clinical trial is investigating a combination of three medications—tafazitamab, lenalidomide, and venetoclax—to see how well they treat patients with mantle cell lymphoma that has returned aft...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States, Rochester, Minnesota, United States

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT ID: NCT06675123

This clinical trial is studying a new treatment for patients with mantle cell lymphoma, a type of cancer that can return after treatment or doesn't respond to previous therapies. The researchers wa...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT ID: NCT06191887

This clinical trial is investigating a new treatment approach for patients with certain types of blood cancers that have returned after treatment or have not responded well to previous therapies. T...

Recruiting

Phase: PHASE1 Type: interventional Locations: Jacksonville, Florida, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions